Viyash Scientific (512529) investor relations material

Leadership and company evolution

• Led by Dr. Haribabu Bodepudi, who has 30 years of pharma experience and a track record of major acquisitions and integrations.

• Originated from the merger of Viyash Life Sciences and Sequent Scientific, combining strengths in human and animal health.

• Expanded rapidly through acquisitions, global partnerships, and R&D investments, filing over 185 patents to date.

• Management team includes experienced leaders across finance, R&D, operations, and business development.

Integrated platform and global presence

• Operates 16 world-class manufacturing facilities across the US, Europe, Brazil, Turkey, and India.

• Backward integrated with strong API and formulation capabilities, serving 150+ countries.

• Holds major regulatory approvals (USFDA, EU-GMP, WHO-GMP, etc.) for both animal and human health products.

• Diverse product portfolio in APIs and formulations, with a focus on complex and high-potency molecules.

Business performance and synergies

• Achieved strong revenue and EBITDA growth post-merger, with FY26 revenue projected at INR 34,203 million and EBITDA at INR 7,025 million.

• Realized significant cost improvements and network synergies through integration of R&D, procurement, and manufacturing.

• Leveraged cross-selling and expanded customer coverage to drive revenue synergies.